🟢 Telix Pharmaceuticals is trading 4.72% up in pre-market after completing 350-patient BiPASS enrollment

Telix Pharmaceuticals is trading at $11.99, +4.72% in pre-market after completing enrollment of 350 patients in its Phase 3 BiPASS study.

• The company aligned with the FDA on an NDA pathway that could support reimbursement and broaden access to prostate-cancer imaging.
• The announcement was explicitly linked to a 5.2% pre-open rise.